A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06121843
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986393 — DRUG
    Specified dose on specified days
  • Alnuctamab — DRUG
    Specified dose on specified days
  • Mezigdomide — DRUG
    Specified dose on specified days
  • Iberdomide — DRUG
    Specified dose on specified days
  • Elranatamab — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Key Dates

Start date
Feb 22, 2024
Status verified
Jan 2026
Primary completion
Aug 1, 2028
Completion
Aug 1, 2028

Study Design

Enrollment
147 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: BMS-986393 + Alnuctamab
  • Experimental: Arm B: BMS-986393 + Mezigdomide
  • Experimental: Arm C: BMS-986393 + Iberdomide
  • Experimental: Arm D: BMS-986393 + Elranatamab

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: Up to 2 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (17)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294-3300
Susan Bal, Site 0008
205-934-1908
Mayo Clinic in Arizona - PhoenixPhoenixArizona85054
Julia Wiedmeier-Nutor, Site 0002
855-776-0015
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010
Myo Htut, Site 0028
626-256-4673
Mayo Clinic in FloridaJacksonvilleFlorida32224
Vivek Roy, Site 0005
000-000-0000
Northside HospitalAtlantaGeorgia30342
Scott Solomon, Site 0006
404-255-1930
Beth Israel Deaconess Medical CenterBostonMassachusetts02215
Jacalyn Rosenblatt, Site 0027
617-667-9920
Dana-Farber Cancer InstituteBostonMassachusetts02215
Omar Nadeem, Site 0011
617-632-3000
Mayo Clinic in Rochester, MinnesotaRochesterMinnesota55905
Taxiarchis Kourelis, Site 0001
855-776-0015
University Of Nebraska Medical CenterOmahaNebraska68198
Christopher D'Angelo, Site 0010
402-559-8110
John Theurer Cancer Center at Hackensack University Medical CenterHackensackNew Jersey07601
David Siegel, Site 0004
551-996-8704
Roswell Park Cancer InstituteBuffaloNew York14263
Ehsan Malek, Site 0007
216-286-4441
Laura and Isaac Perlmutter Cancer CenterNew YorkNew York10016
Jingmei Hsu, Site 0022
646-501-4848
Local Institution - 0009New YorkNew York10032-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Sham Mailankody, Site 0012
646-608-3712
Local Institution - 0023PittsburghPennsylvania15232-
Tennessee OncologyNashvilleTennessee37203
Jesus Berdeja, Site 0025
615-329-0570
University of Texas MD Anderson Cancer CenterHoustonTexas77030
Krina Patel, Site 0003
713-792-6662

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Alabama at Birmingham· Birmingham, ALMayo Clinic in Arizona - Phoenix· Phoenix, AZCity of Hope Comprehensive Cancer Center· Duarte, CAMayo Clinic in Florida· Jacksonville, FLNorthside Hospital· Atlanta, GABeth Israel Deaconess Medical Center· Boston, MA

Related Studies